Novartis Looks To Bring First-In-Class Vascular Disrupting Agent To Market
Company will move the oncologic into Phase III in non-small cell lung cancer in 2008 under a deal with Antisoma, potentially worth more than $890 million.
Company will move the oncologic into Phase III in non-small cell lung cancer in 2008 under a deal with Antisoma, potentially worth more than $890 million.